FDA Guidance: What it Means for AMD Clinical Trials

In an article with Retina Today, Chief Medical Officers Nadia Waheed, MD, MPH, (Ocular Therapeutix, Inc.) Ramiro Ribeiro, MD, PhD, (EyePoint) and Victor Chong, MD, MBA, (Clearside Biomedical, Inc.) discuss the recent shifts in AMD clinical trials and their latest interactions with regulatory bodies. Lexitas Chief Medical Officer, David Tanzer, MD, ABO, provides his input on the draft guidance’s potential impact on AMD clinical trial design and the AMD trial landscape, emphasizing the importance of continued collaboration with the FDA.

Our Visionary Insights newsletter is published once a month and has thousands of subscribers. To stay in touch, subscribe today.